Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 5NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 5Gastrointestinal 3Dermatologic 3Thoracic 2Sarcoma 2Other hematologic neoplasm 2Lymphoid 2CNS 2Breast 2Plasma cell 1Other solid neoplasm 1NET 1Myeloid 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Neuroendocrine Tumors 117Gastro-enteropancreatic neuroendocrine tumor 21Neoplasms 20Carcinoid Tumor 17Colorectal Neoplasms 13Carcinoma, Neuroendocrine 11Neoplasm Metastasis 10Carcinoma 10Lung Neoplasms 9Small Cell Lung Carcinoma 8Prostatic Neoplasms 8Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 8Sarcoma 7Pancreatic Neoplasms 7Carcinoma, Hepatocellular 7Adenoma, Islet Cell 7Stomach Neoplasms 6Serotonin Syndrome 6Pheochromocytoma 6Melanoma 6Head and Neck Neoplasms 6Digestive System Neoplasms 6Cholangiocarcinoma 6Thyroid Neoplasms 5Paraganglioma 5Ovarian Neoplasms 5Gastroenteropancreatic Neuroendocrine Tumors 5Colonic Neoplasms 5

Interventions

epothilone B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Vipoma × NET × Clear all
NCT00050349 2017-03-01

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Novartis

Phase 2 Completed
33 enrolled
EndocrineNET

Carcinoid Tumor, Carcinoma, Vipoma, Neoplasm Metastasis, Neoplasms, Gastrinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡